3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
4
NETWORK
2
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
75
Neoplasms
15
Neoplasm Metastasis
9
Advanced Breast Cancer
5
Neoplasms by Site
3
Breast Diseases
3
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
2
Patient Compliance
2
Ovarian Neoplasms
2
Endometrial Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Skin Diseases
1
Recurrence
1
Quality of Life
1
Osteoporosis
1
Multiple Endocrine Neoplasia Type 1
1
Low Grade Serous Ovarian Cancer
1
Lethal Congenital Contracture Syndrome 2
1
Joint Diseases
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms, Male
1
Breast Cancer Metastatic
1
Bone Diseases, Metabolic
1
Bone Density
1
Arthralgia
1
Advanced Metastatic Breast Cancer
1
Interventions
exemestane
2
Letrozole
2
seviteronel
1
sargramostim
1
ribociclib
1
methyl N-acetylsibirosaminide
1
elacestrant
1
Trastuzumab
1
Tamoxifen
1
Suspensions
1
Receptor Protein-Tyrosine Kinases
1
Presenilin-1
1
Pemetrexed
1
Leuprolide
1
Injections
1
HER2 peptide (369-377)
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Goserelin
1
Fentanyl
1
Anastrozole
1
90Y-octreotide, DOTA-Tyr(3)-
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Breast Neoplasms, Male
×
Anastrozole
×
Clear all
NCT06492616
2026-05-27
ELEGANT
Stemline Therapeutics, Inc.
Phase 3
Recruiting
4,220 enrolled